A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis — Active Not Recruiting • Phase III • Dermatology • NCT06832618.
• Ruxolitinib cream safely and effectively reduced moderate eczema in children and teenagers aged 6-17 years.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

• Quick orientation before opening the registry record.
• Checking recruitment status, phase and sponsor at a glance.
• Connecting this trial to nearby guidelines, Drug Science and education.